Biotech Specialty Pharma

NanoViricides, Inc.

135 Wood Street
West Haven, CT 06516 USA
Phone
Fax
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Anti-viral drugs to fight HIV, influenza, and other infections

Management Eugene Seymour, MD, MPH, CEO; Anil R. Diwan, PhD, Chairman & President; Randall Barton, PhD, Chief Science Officer; Jayant Tatake, PhD, Vice President of Research and Development; Krishna Menon, PhD, VMD, MRCS, Chief Regulatory Officer Directors/Advisory Board (Names/Titles Only): Anil R. Diwan, PhD, Chairman & President of NanoViricides, Inc. Eugene Seymour MD, MPH, CEO of NanoViricides, Inc. Stanley Glick, BBA, CPA, Chairman of Audit Committee Milton Boniuk, MD, The Caroline F. Elles Chair Professor of Ophthalmology, Baylor College of Medicine, Houston, TX Mukund S. Kulkarni, Professor and Chancellor at Penn State University ? Harrisburg

Click here for Financial Data
Keywords: anti-viral drugs, HIVAIDS, dengue, influenza, herpes, adenovirus, keratitis, Immunology, DrugDelivery, infectiousdiseases

Comment


Updated: Oct. 22, 2015


Description

NanoViricides is developing broad-spectrum anti-influenza drugs as part of its rich drug pipeline. The Company believes that its FluCide drug candidates will be effective against most if not all influ......view more

Products / Services

FluCide-I (Influenza A) HivCide-I (HIV/AIDS) DengiCide-I (Dengue/dengue hemorrhagic fever) HerpiCide-I (For ocular herpes infections) EKC-Cide-I (For ocular adenovirus infe......view more

Technology / Differentiation

NanoViricides Inc. has full license to TheraCour technologies for developing nanotechnology-based targeted anti-viral therapeutics....view more

Market / Customers

Human Immunodeficiency Virus therapeutic sales accounts for 61% of the global anti-viral therapeutic market. The anti-viral therapeutic market is estimated to reach $30.1B by 2017.......view more


Competitors / Substitutes / Alternatives

The anti-viral therapeutics field is highly competitive, with pharmaceutical firms such as Gilead, Merck, GlaxoSmithKline, Roche and Bristol Myers Squibb pursuing different technologies including inhi...view more

Strategy

Develop and test drug candidates in animals, then file data with the FDA for permission to move to human trials. The Company will consider licensing each drug after the completion of Phase 2a human tr...view more

Revenue / Funding

Spent $17M in 5 1/2 years with 9 drugs in pipeline of which there are 5 lead candidates for eventual FDA submission. At historical spending levels, the Company has 3 years of cash in the bank although...view more

RELATED COMPANIES